When: Confirmed close above $27.22 with expanding volume

Then: Smaller size with tight $26.50 stop

Hold existing position; no new adds at $26.80; scale-in at $25.70 and $25.40 on confirmation; stop at $24.50

• Hold existing position for 6.46% dividend yield at current prices
• No new adds at $26.80 - risk-reward is asymmetric to the downside
• Scale-in levels at $25.70 and $25.40 are correct as drafted - do not tighten
• Stop at $24.50 is appropriate
• Require daily close at or above scale-in levels before adding, not intraday tag
• Resistance at $27.22 already rejected; stock did not break out, it bounced
• RSI of 67 after 16.5% rally in 5 weeks is late-cycle momentum, not neutral
• Stock at upper Bollinger band; confluence of extended indicators
• Cumulative impairments of $8.8 billion across 4 quarters (~ $2.2 billion quarterly average); no evidence cycle has concluded
• Q2 2026 impairment charge was $4.3 billion - most recent data point
• Forward EPS recovery to $2.90 is consensus-dependent; denominator risk if EPS disappoints
• Pipeline realistic new revenue of $5-8 billion does not close gap against $10-15 billion Eliquis LOE pressure
• Eliquis LOE is 2026-2027 - on the doorstep
• 50 SMA at $24.84 is structural support level that matters
• Lower Bollinger band at $23.57
• CEO $1 million purchase is sentiment signal only, not a thesis
• IRA negotiation pressure continues to weigh on Big Pharma multiples
• PFE has materially lagged S&P 500 year-to-date

→ vs aggressive: Bull flag pattern rejected - $27.05 was a test of resistance that failed, not a breakout followed by consolidation; the stock bounced off the same $27.22 ceiling it already rejected

→ vs aggressive: RSI 67 after 16.5% rally in 5 weeks is late-cycle momentum, not neutral; standard overbought threshold is 70, not 80 with negative divergence

→ vs aggressive: Forward PE of 9.3x assumes consensus EPS holds; denominator risk is real if impairments continue or Seagen ramps slower than expected

→ vs aggressive: Cumulative impairments of $8.8 billion over 4 quarters (~ $2.2B quarterly average); Q2 2026 alone was $4.3 billion - no evidence this cycle has concluded

→ vs aggressive: Pipeline revenue gap is $5-8 billion realistic new revenue against $10-15 billion Eliquis pressure - LITFULO vitiligo is incremental, not transformational; Seagen oncology unproven at commercial scale

→ vs aggressive: Waiting for $25.40 does not mean buying less yield - it means higher yield on cost (~6.8% vs 6.46%) and wider margin of safety with structural support at 50 SMA

→ vs aggressive: Tightening scale-in from $25.70/$25.40 to $26.17 raises probability of adding into a position that immediately goes against you; original levels are calibrated to where stock historically finds buyers

→ vs aggressive: CEO $1 million purchase is ~ rounding error relative to total compensation, single transaction, historically weak predictive value for short/medium term

→ vs aggressive: Retail silence does not mean absence of sellers - absence of retail means absence of marginal buyers, not a guaranteed upside setup

→ vs aggressive: Framing shift from 'coin flip' to 'high-conviction income hold with tactical breakout' is rhetoric, not analysis; underlying facts have not changed

HOLD existing position; scale-in tiers at $26.17 (10 EMA confirmation), $25.40 (value zone), and $27.22 (breakout trigger) with $24.50 stop loss

• Forward PE of 9.3 is meaningfully cheap on normalized earnings power
• Record-low S&P yields and falling ten-year yields create defensive bid for cash flow
• Most recent impairment was $4.32B last quarter, impairment cycle not definitively concluded
• Current yield of 6.46% scales to 6.8% at $25.40 (34 basis point pickup)
• RSI at 67 in context of 16.5% rally in five weeks suggests stretched momentum
• August 10 action was failed resistance test, not bull flag (no pole, no decisive breakout)
• CEO Albert Bourla bought $1M personally at multi-year operational sentiment low
• LITFULO vitiligo label expansion combined with Seagen ramp and Biohaven migraine execution provides directional evidence
• IRA pressure affects ABBV, JNJ, AMGN equally; Pfizer's specific challenges are patent cliff and impairment cycle
• Macro tailwind for defensive yield undiminished by sector politics

→ vs aggressive: Bull flag pattern identification is wrong—no pole or decisive breakout; August 10 was failed resistance test at $27.05 vs $27.22 upper band

→ vs aggressive: RSI threshold redefinition to 80 with divergence is intellectually loose; standard is 70

→ vs aggressive: Impairment cycle characterization as 'rearview' is unsupported; $4.32B most recent and third impairment could further muddy denominator

→ vs aggressive: Retail silence argument is a story, not a rule; absence of signal tells nothing about marginal institutional flows

→ vs conservative: $25.40 anchor ignores opportunity cost of potential 5% rally to $28-$29 if $27.22 breaks next week

→ vs conservative: CEO buy ($1M at multi-year low) deserves more weight than statistical regression framing—context of Q2 impairments makes it a contrarian signal

→ vs conservative: Two clean GAAP quarters required before adding is inflexible; forward PE of 9.3 already prices in impairment uncertainty

→ vs conservative: LITFULO vitiligo expansion is directional evidence for immunology franchise recovery when viewed as portfolio with Seagen and Biohaven